EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review

José Luis Patier-de la Peña

Rare Diseases and Therapeutics · 18.11.2026 · 1 (1) · 2

DOI: 10.3390/rdt1010002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rare Diseases and Therapeutics, online erschienen am 18.11.2026. Verfasst von José Luis Patier-de la Peña. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterised by abnormal angiogenesis caused by dysregulation of the BMP9/10–ALK1–ENG–SMAD signalling axis. The principal clinical manifestations are recurrent epistaxis, iron-deficiency anaemia, gastrointestinal bleeding and visceral arteriovenous malformations. Improved understanding of the molecular mechanisms underlying endothelial dysfunction has enabled the development of targeted therapeutic approaches that modulate angiogenic pathways involved in disease progression.

Methods

A narrative review was undertaken from clinical and translational perspectives. PubMed/MEDLINE, Scopus, Web of Science and ClinicalTrials.gov were searched for records published from January 2012 to May 2026. Medical Subject Headings (MeSH) and free-text terms related to HHT, angiogenesis, VEGF, FGFR, PI3K/AKT/mTOR, ANGPT2 and established or emerging therapies were used. Priority was accorded to randomised clinical trials, prospective studies, observational cohorts, systematic reviews, meta-analyses, international guidelines and consensus statements.

Results

Bevacizumab remains the systemic anti-VEGF therapy with the strongest clinical evidence in severe bleeding, transfusion-dependent anaemia and symptomatic hepatic vascular involvement. Pomalidomide is supported by the most robust randomised evidence for reducing moderate-to-severe epistaxis and improving quality of life. Multikinase inhibitors, including nintedanib and pazopanib, together with tacrolimus, sirolimus and beta-blockers, have broadened the range of therapeutic options, although several approaches require further validation. Most recently, the AKT inhibitor engasertib achieved clinically meaningful reductions in epistaxis frequency and duration, thereby providing the first direct clinical validation of AKT as a therapeutic target in HHT. Emerging strategies directed at ANGPT2/Tie2 and other vascular-stabilisation pathways may further expand future treatment options.

Conclusions

HHT management is progressively shifting towards a precision-medicine model that integrates genotype, haemorrhagic phenotype, visceral involvement, angiogenic biomarkers and treatment tolerability. Bevacizumab and pomalidomide are currently the best-established systemic therapies, whereas AKT inhibition is among the most promising recent developments. Further progress will require international collaboration, standardised outcome measures, biomarker-guided patient selection and prospectively validated and individualised treatment strategies.

Zitieren

APA

Peña, J. L. P. L. (2026). Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review. Rare Diseases and Therapeutics, 1(1), 2. https://doi.org/10.3390/rdt1010002

Vancouver

Peña JLPL. Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review. Rare Diseases and Therapeutics. 2026;1(1):2. doi:10.3390/rdt1010002

BibTeX
@article{Pea2026,
  author = {Peña, José Luis Patier-de la},
  title = {Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review},
  journal = {Rare Diseases and Therapeutics},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {2},
  doi = {10.3390/rdt1010002}
}
Kostenlos starten →